Su
No verificado

Summit Therapeutics

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud
18/11/2026
Análisis de Mercados
Industria
Ciencia
BiotecnologĂ­a
Farmacéutica
OncologĂ­a
Sanidad
Salud
Medicina - Varios
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
1.00
15/11/2026
Industria
Ciencia
BiotecnologĂ­a
Farmacéutica
OncologĂ­a
Salud
Higiene alimentaria
Medicina - Varios
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
1.00
04/11/2026
Web y redes sociales
TelefonĂ­a
Mercado de valores
Ciencia
Medicina - Varios
Sanidad
BiotecnologĂ­a
Farmacéutica
Salud
OncologĂ­a
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
1.00
23/10/2026
Sanidad
Ciencia
Farmacéutica
TecnologĂ­a
OncologĂ­a
Software
Técnica
GestiĂłn empresarial
Medicina - Varios
Higiene alimentaria
BiotecnologĂ­a
Salud
Industria
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
1.00
22/10/2026
Ciencia
Medicina - Varios
BiotecnologĂ­a
Sanidad
Salud
Farmacéutica
OncologĂ­a
Eventos
Industria
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
1.00
21/10/2026
Ciencia
Medicina - Varios
Sanidad
BiotecnologĂ­a
Farmacéutica
Salud
OncologĂ­a
Mercado laboral
Eventos
Industria
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
1.00
19/10/2026
Ciencia
Medicina - Varios
BiotecnologĂ­a
Salud
Farmacéutica
Sanidad
OncologĂ­a
Industria
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
1.00
05/10/2026
Mercado laboral
OncologĂ­a
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
BiotecnologĂ­a
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
1.00
02/10/2026
Mercado laboral
Ciencia
Medicina - Varios
Sanidad
BiotecnologĂ­a
Farmacéutica
Salud
OncologĂ­a
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
1.00

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0